TRAX financial statements
The full income statement, balance sheet, and cash-flow statement for First Tracks Biotherapeutics Inc. Ordinary Shares (TRAX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
| Line item | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Income Statement | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 34.9M | 52.8M | ||
| Research & development | 25.6M | 34.0M | |
| Selling, general & administrative | 9.29M | 18.9M | |
| General & administrative | 9.29M | 18.9M | |
| Operating income | -34.9M | -52.8M | |
| Other non-operating income | -1.00K | -1.00K | |
| Net income | -33.4M | -50.5M | |
| -$0.95 | — | ||
| EPS (basic) | -$0.95 | — | |
| Weighted-avg shares (basic) | 35.0M | — | |
| Weighted-avg shares (diluted) | 35.0M | — | |
| Balance Sheet | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| 178M | 289M | ||
| Cash & equivalents | 168M | 248M | |
| Prepaid expenses | 9.73M | 2.95M | |
| Other current assets | 2.18M | — | |
| 183M | 291M | ||
| Property, plant & equipment | 1.07M | 1.17M | |
| Operating lease right-of-use | 4.32M | 0.00 | |
| Other non-current assets | 0.00 | 0.00 | |
| 12.4M | 33.1M | ||
| Accounts payable | 2.55M | 7.50M | |
| Accrued liabilities | 7.46M | 25.6M | |
| Current lease liability | 2.44M | 0.00 | |
| Non-current lease liability | 1.90M | 0.00 | |
| Operating lease liability (total) | 4.33M | — | |
| 169M | 257M | ||
| Preferred stock | 0.00 | — | |
| Common stock | 35.0K | — | |
| Additional paid-in capital | 193M | — | |
| Retained earnings | -24.6M | — | |
| Accumulated other comprehensive income | 0.00 | -146K | |
| Total liabilities & equity | 183M | 291M | |
| Common shares issued | 35.4M | — | |
| Common shares outstanding | 35.4M | — | |
| Shares outstanding (cover) | 35.7M | 34.9M | |
| Cash Flow | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| -31.9M | -32.6M | ||
| Depreciation & amortization | 105K | 125K | |
| Share-based compensation | 8.32M | 11.5M | |
| -25.0K | 35.0M | ||
| Capital expenditure | 25.0K | 17.0K | |
| Free cash flow | -31.9M | -32.6M | |
| Acquisitions | 0.00 | 0.00 | |
| -48.5M | 7.85M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 109M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Net change in cash | -80.5M | 10.3M | |
| Valuation Ratios | as ofJun 30 ’26 | as ofMar 31 ’26 | |
| Market cap | 719M | — | |
| P/B | 4.3× | — | |
| Source filing | 10-Q | 10-Q |
About this data
Source: TRAX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all TRAX filings on SEC EDGAR → Not investment advice.